Skip to main content

Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors



SARS-CoV2 can induce a strong host immune response. Many studies have evaluated antibody response following SARS-CoV2 infections. This study investigated the immune response and T cell receptor diversity in people who had recovered from SARS-CoV2 infection (COVID-19).


Using the nCounter platform, we compared transcriptomic profiles of 162 COVID-19 convalescent donors (CCD) and 40 healthy donors (HD). 69 of the 162 CCDs had two or more time points sampled.


After eliminating the effects of demographic factors, we found extensive differential gene expression up to 241 days into the convalescent period. The differentially expressed genes were involved in several pathways, including virus-host interaction, interleukin and JAK-STAT signaling, T-cell co-stimulation, and immune exhaustion. A subset of 21 CCD samples was found to be highly “perturbed,” characterized by overexpression of PLAU, IL1B, NFKB1, PLEK, LCP2, IRF3, MTOR, IL18BP, RACK1, TGFB1, and others. In addition, one of the clusters, P1 (n = 8) CCD samples, showed enhanced TCR diversity in 7 VJ pairs (TRAV9.1_TCRVA_014.1, TRBV6.8_TCRVB_016.1, TRAV7_TCRVA_008.1, TRGV9_ENST00000444775.1, TRAV18_TCRVA_026.1, TRGV4_ENST00000390345.1, TRAV11_TCRVA_017.1). Multiplexed cytokine analysis revealed anomalies in SCF, SCGF-b, and MCP-1 expression in this subset.


Persistent alterations in inflammatory pathways and T-cell activation/exhaustion markers for months after active infection may help shed light on the pathophysiology of a prolonged post-viral syndrome observed following recovery from COVID-19 infection. Future studies may inform the ability to identify druggable targets involving these pathways to mitigate the long-term effects of COVID-19 infection.

Trial Registration: Registered April 24, 2020.


Respiratory viral infections are associated with a robust immune response. Initial activation of the innate immune response leads to the release of cytokines and chemokines. Subsequent activation of the adaptive immune response results in the production of cytotoxic T-cells directed toward virus-infected cells and B-cells that produce pathogen virus-antibodies. Following the resolution of the infection, virus-specific antibodies and cytotoxic T-cells persist, but the acute immune response resolves within days or weeks after the virus is cleared [1,2,3]. However, for chronic viral infections, the immune response persists, and T-cells can develop an exhausted phenotype.

Individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) often experience severe respiratory complications and other sequelae. SARS-CoV-2 infection results in dysregulation of the innate and adaptive immune response [4, 5]. Acute infection is associated with T-cell depletion and exhaustion, which contributes to SARS-CoV-2 persistence. More severe clinical disease is associated with greater lymphopenia [6], and recovery of lymphocyte counts precedes clinical recovery [4]. Compared to other respiratory viral infections, the immune response to SARS-CoV-2 is characterized by robust production of proinflammatory cytokines but diminished interferon Type I and III responses [7, 8]. Molecular and cellular immune features of 31 patients aged > 70 years with severe COVID-19 pneumonia have suggested that inflammation, coupled with the inability to have a proper anti-viral response, could aggravate disease severity and the worst clinical outcome [9]. Comparative host transcriptome analysis across distant coronavirus genres showed 23 pathways and 21 Differentially expressed genes (DEGs) across ten immune response-associated pathways were shared by these viruses, and these DEGs could be utilized as specific targets for novel coronavirus treatments [10].

Studies involving the convalescent period following acute viral/bacterial infections offer significant insights into disease pathophysiology, duration of immunity, host characteristics facilitating recovery, as well as susceptibility for recurrence/reinfection. In a prospective study evaluating transcriptomics of 1610 healthy subjects, 142 of whom developed an acute viral respiratory illness (influenza A, B, rhinovirus, or other) over a 2-year period, the infective phase (days 1–2) demonstrated a spike in interferon and innate immunity pathways, followed by a recovery phase characterized by transcripts implicated in cell proliferation and repair (days 4–6). By day 21, gene expression was indistinguishable from baseline in this study [1]. In another study of patients who had recovered from Ebola virus infections, a small panel of genes identified via transcriptomics were predictors of outcomes and survival, independent of viral load [11]. In a third study of convalescence, global transcriptome analysis identified diagnostic signatures for resolution and symptom persistence in Lyme disease [12].

The post convalescent period of SARS-CoV2 infections is an area of active interest. In a recent cohort study of COVID-19 infected subjects, 90% of whom had mild illness or were asymptomatic, 30% eventually reported symptoms such as fatigue, loss of taste or smell or brain fog, and an overall decrease in health-related quality of life measures up to 6 months after the acute phase [13]. Several groups have investigated the course of the antibody response of patients recovering from SARS-CoV-2 infections [14], but little is known about the recovery of transcriptomic changes in this rather protracted post-acute period in large cohorts.

We profiled peripheral blood leukocyte gene expression in people who had been infected with SARS-CoV-2 and who had recovered and were donating COVID-19 convalescent plasma. Gene expression was analyzed using the nCounter platform, a robust tool to detect the expression of 800 genes in a single reaction with high sensitivity and linearity across a broad range of expression levels. This methodology bridges the gap between genome-wide (microarrays or RNA sequencing) and targeted (real-time quantitative PCR) expression profiling [15]. Gene signatures identified on this platform have demonstrated clinical applicability in diagnostics [16] and in understanding and predicting responses to therapeutic interventions [17, 18]. Recently, the platform was utilized successfully to risk-stratify patients with active COVID-19 infections based on data from a small study [19]. We sought to investigate the transcriptome of peripheral blood post-COVID-19 in the context of other demographic, clinical, and laboratory parameters. In this study, we evaluated the immune response in COVID-19 convalescent donors (CCD). Towards this goal, using the nCounter, we analyzed and compared the transcriptomes of 162 CCD and healthy donors (HD).


Human subjects and eligibility criteria

Between April-December 2020 (i.e., before the COVID-19 vaccination), 162 CCD and 40 healthy donor controls were enrolled prospectively in an IRB-approved protocol (Clinical Trials Number: NCT04360278) and provided written informed consent to participate in the study. Of the 162 CCD subjects, 93 subjects donated blood once, while 46 donated twice, 12 thrice, 6 four times, and 5 donated five times.

Eligibility criteria for CCD included (1) routine blood donor criteria, (2) molecular or serologic laboratory evidence of past COVID-19 infection, and (3) complete recovery from COVID-19, with no symptoms other than residual loss of taste or smell for ≥ 28 days, or ≥ 14 days with a negative molecular test after recovery and was considered as the first visit post convalescence. We collected donor demographic and biometric data, including age, race, sex, ABO blood type, body mass index, and complete blood counts at the first visit for each subject in the early convalescent period. For each CCD, clinical severity of past COVID-19 infection was categorized as asymptomatic, mild (self-limiting course, symptomatic management at home), moderate (emergency room management or hospitalization), or severe (ICU admission). In all cases, anti-SARS-CoV-2 testing was performed. The minimum interval between plasma donations was 28 days; shorter intervals were acceptable between sample draw visits. Routine plasma donor testing was performed, including standard infectious disease testing, blood group assessment, and human leukocyte antigen antibody testing in female donors. Healthy donor control samples were obtained from research donors (protocol 99-CC-0168) who previously provided consent for the collection of research blood samples and had self-reported to be negative for SARS-CoV-2 exposure.

Anti-SARS-CoV-2 testing was performed using the Ortho-Clinical Diagnostics VITROS® Total (IgA/G/M) and IgG COVID-19 Antibody tests, as well as the SARS-CoV-2 neutralizing assay (NIH/National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility at Fort Detrick, Maryland, USA) as previously described [20].

RNA isolation

Five to ten milliliters of human whole blood samples were collected in EDTA-anticoagulated tubes (BD) and centrifuged at 2500 RPM for 15 min. The supernatant plasma was separated for the antibody and multiplex immunoassays. ACK lysis buffer (Quality Biological) was added to the leftover pellet in a 1: 9 concentration, mixed several times, and incubated at room temperature for 15 min. Subsequently, the tubes were centrifuged at 1500 RPM for 10 min, and the supernatant was discarded. The pellet was washed twice with 1XPBS (KD Medical). 700 µL QIAzol lysis reagent (Qiagen) was added to the pellet with mixing and stored at −80 °C. Using the RNeasy Mini Kit (Qiagen), RNA was eluted in 40 µL of Milli-Q water. Following quality (Agilent 2100 Bioanalyzer) and quantity (Nanodrop One, Thermo Scientific) checks, the RNA was stored at −80 °C for further transcriptomic profiling.

Nanostring nCounter transcriptomic profiling

Nanostring transcriptomic profiling was performed using the nCounter® Human Host Response (Additional file 1: Table S1) and the nCounter® Human TCR diversity panels (Additional file 2: Table S2). Whole blood total RNA (100 ng) was hybridized to reporter and capture probes at 65 °C for 16 h using a thermal cycler (Veriti Applied Biosystems). These hybridized samples were loaded onto the nCounter cartridge, and the post hybridization step and scanning were performed on the nCounter Prep Station and Digital Analyzer.

Multiplex immunoassay

In a subset of CCD samples with highly perturbed gene expression and in healthy donor controls, we performed cytokine analysis. According to the manufacturer's instructions, a multiplex biometric immunoassay was performed to assess 48 cytokine and chemokine cell signaling molecules (Bio-Plex Human Cytokine Assay; Bio-Rad Inc., Hercules, CA, USA) [21]. The quantified cytokines included interleukins (IL-1α, IL-1β, IL-1Ra, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, & IL-18), interferons (IFN-α2 & IFN-γ), tumor necrosis factors (TNF-α, TNF-β, & TRAIL), growth factors (SCF, FGF, β-NGF, HGF, LIF, PDGF-BB, VEGF, SCGF- β, G-CSF, M-CSF, & GM-CSF), and chemokines (CCL247CTACK, eotaxin, GRO-α, CXCL10/IP-10, CCL2/MCP-1, CCL7/MCP-3, MIF, MIGCCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, & SDF-1α). A multiplex array reader from Luminex™ Instrumentation System (Bio-Plex 200 system) was used to determine the cytokine levels. The Bio-Plex Manager Software was used to calculate the cytokine concentrations.

Data processing for nCounter host response panel

All statistical analyses were performed using R (Version 4.1.1). Raw counts were normalized by scaling each sample by its geometric mean of the panel’s 12 housekeeping genes. Of the 270 samples from CCDs, we removed 2 samples with low signal strength, defined as low outlier values of the housekeeper geometric mean. The normalized data were then log2-transformed. Healthy donor samples were compared to CCD across 4 time windows: 26–89 days, 90–119 days, 120–149 days, and 150–241 days post-symptoms-onset. Within each window, a linear mixed model was fit to each gene’s normalized log2-transformed expression. The model treated CCD/healthy donor status, age, sex, and race as fixed effects and patient ID as a random effect. No patients had multiple samples within the 120–149 day window, so in this window, a linear model was fit with no random effects. The R library lmerTest was used to fit mixed models, and the R function lm was used to fit linear models. For each window, all genes’ p-values were converted to False Discovery Rates using the Benjamini–Hochberg procedure, using the R function p.adjust.

Classification of highly perturbed samples

To calculate perturbation scores, we began by standardizing the data to give each gene mean 0 and standard deviation 1 within the healthy donor samples. We then defined a perturbation score as each sample’s Euclidean distance from the mean healthy donor sample in this standardized expression data. To define “highly perturbed” samples, we used the R library Mclust to cluster perturbation scores into two clusters, one high and one low. The highly perturbed samples were clustered into groups P1 and P2 by applying the R functions hclust and cutree to their log2-transformed normalized expression data.

Analysis of nCounter TCR diversity panel

TCR diversity scores were calculated using the Rosalind nCounter TCR Diversity Report, a software tool designed specifically for the nCounter TCR diversity panel. The software calculates the Shannon diversity index for each sample’s TCR gene counts. Gene expression values are first normalized to a “panel standard” reference sample to remove variability due to batch effects. TCR diversity scores were analyzed using the same statistical models applied to gene expression values.


Demographics and clinical characteristics

Whole blood samples were collected from 270 donations by CCD and 40 contemporaneously recruited healthy donors from April to December 2020. The 270 CCD donations were consecutive, and they were from 162 donors. Among the 162 CCD, 93 donated once, and 69 donated more than once. All 40 healthy donors only donated once.

Age, sex, ethnicity, and Body Mass Index (BMI) distributions were similar among the 162 CCD and 40 healthy donors (Table 1). With respect to baseline complete blood counts, hemoglobin, platelets, and absolute basophil and eosinophil counts were similar among CCD and healthy donors. However, despite sample collections occurring over several months after convalescence, mean counts for absolute neutrophil counts (ANC), absolute monocyte counts (AMC), and absolute lymphocyte counts (ALC) were significantly higher among CCD compared to healthy donors (Table 1). Cell counts were collected earlier post convalescence for CCD only with their first donation. Among the CCDs, most had mild disease, and anti-SARS-CoV2 levels were highly variable. Some CCDs donated up to 5 times (Table 2).

Table 1 COVID-19 Convalescent Donor Demographics and Blood Counts
Table 2 Number of Donations by COVID-19 Convalescent Plasma Donors and Clinical Characteristics of Their Infections

Age, ethnicity, sex, BMI, and baseline cell counts, as well as ABO blood groups, disease severity and mean total and IgG antibodies, and median neutralizing antibody titers are summarized for CCD donating multiple times (Table 3). Serial antibody titers of individuals who donated 1, 2, 3, 4, or 5 times are shown in Additional file 5: Fig. S1, A-C. The total mean antibody levels increased at the last donation compared to the first donation [Signal/Cutoff (S/Co) 495.0 ± 315.3 versus 376.6 ± 276.4, p < 0.0001]. Otherwise, no differences were observed in this cohort of individuals with respect to changes in antibody titers over collections or when evaluated by other parameters.

Table 3 COVID-19 Convalescent Plasma Donor Demographics Based on Number of Donations

Gene expression remains altered for months after infection

CCD samples were stratified into 4 groups based on time since symptoms onset: 26–89 days, 90–119 days, 120–149 days, and 150–241 days. For each gene within each of these groups, a linear mixed model was fit comparing log2-transformed expression levels in CCD vs. healthy donors, adjusting for age, sex, and race, and treating donor ID as a random effect. Results from these models are in Additional file 3: Table S3.

All CCD time windows saw multiple genes with highly statistically significant changes from healthy donors (Fig. 1A). From the panel’s 775 non-housekeeper genes, a fold-change of > 20% and a False Discovery Rate < 0.05 were found for 85 genes in the 26–89-day window (n = 77), 87 genes in the 90–119-day window (n = 56), 178 genes in the 120–149-day window (n = 60), and 30 genes in the 150–241-day window (n = 58).

Fig. 1
figure 1

Differential expression of CCD vs. HD. A. Log2 fold-change and -log10(p-value) of the expression of genes in CCD vs. HD. CCD samples were partitioned into 4 groups based on days post-onset of symptoms, and each group was analyzed separately. B. Expression of all genes achieving a fold change of > 50% and a False Discovery Rate < 0.05, estimated log2 fold-change vs. HD by time window. Side bars show gene set membership. C. Expression of selected genes by time window. Point color shows CCD (orange) vs. HD (blue), and blue lines show the mean and 0.1/0.9 quantiles of HD expression

28 genes departed from the healthy donor mean by > 50% and with FDR < 0.05 in at least one time window (Fig. 1B). These genes participate in diverse biological pathways. While some genes gradually but monotonically return to healthy donor levels, others see their greatest departures from healthy donor expression 120–149 days after onset of symptoms (Fig. 1C). The genes with the greatest average departures from healthy donors include CTLA4, CXCR4, OSM, CXCL2, CCL3/CCL3L1/CCL3L3, IFNA6, and HERC5. CTLA4 and CXCR4 begin upregulated above healthy donor medians and gradually return to normal (Fig. 1C).

Two clusters of CCD samples with “highly perturbed” gene expression demonstrate aberrant cytokine expression

In efforts to further study these persistent or recurring and prolonged gene expression aberrations, we sought to delineate samples with immune states perturbed far beyond the average trend. We defined a perturbation score based on the Euclidean distance of each sample’s expression profile from the mean healthy donor sample (Methods). Average CCD perturbation scores were elevated at early time points and returned to the mean healthy donor levels by 200 days (Fig. 2A). CCD perturbation scores were highly right tailed, with a subset of samples from ~ 150 days post-symptoms onset falling far above the healthy donor range. Model-based clustering partitioned the perturbation scores into a large group of “typical” samples and a group of 21 “highly perturbed” CCD samples. This study cannot definitively attribute these highly perturbed immune states to earlier COVID-19; however, detailed donor history and the need for complete absence of symptoms during repeat donations preclude the possibility of re-infections as cause for these changes. Additionally, the study period (carried out early in the pandemic) ruled out the possibility of vaccine induced changes. With this caveat, the below results may offer clues to COVID-convalescent immune dysregulation.

Fig. 2
figure 2

Subset of samples with highly perturbed expression profiles. A. Perturbation scores plotted over time. Point color shows CCD/HD status and clustering results from 21 highly perturbed samples. Blue lines show the mean and 0.1/0.9 quantiles of HD samples. B. Gene expression in highly perturbed samples, standardized to the mean and SD of the HD samples. The 20 most upregulated and down-regulated genes in each cluster are shown. C. Expression of genes characteristic of P1 and P2. Blue lines show the mean and 0.1/0.9 quantiles of HD expression

The 21 highly perturbed samples fell into 2 distinct clusters based on their expression profiles. Cluster “P1” (8 samples) was characterized by high expression of PLAU, IL1B, NFKB1, PLEK, LCP2, and other genes (Fig. 2B, C). In a study of time-order transcriptomics to characterize molecular mechanisms which underpin multiple organ dysfunction in COVID-19, PLAU (plasminogen activator, urokinase) was among the genes to induce olfactory and neurological dysfunction [22]. NFKB1, an NF-κB signaling pathway gene, has been involved in the upregulation of inflammatory responses in patients with COVID-19 infection, with TLR4 acting as an intermediary. Additionally, despite a diminished IFN-I response, robust cytokine production and viral replication in SARS-CoV-2 infection are thought to be due to virus-mediated activation of NF-κB in the absence of other canonical IFN-I-related transcription factors [23,24,25]. PLEK and LCP2 genes which code proteins, pleckstrin and lymphocyte cytosolic protein 2, respectively, may play a role in COVID-19 pathogenesis [26, 27].

Cluster “P2” (13 samples) was characterized by high expression of IRF3, MTOR, IL18BP, RACK1, TGFB1 and others. TLR3 and TLR4 activate IRF3 (Interferon Regulatory Factor 3) during the viral attack, triggering the type I interferons (IFN-1) transcription and NF-κB activation through the TRIF-dependent pathway during SARS-CoV-2 [28]. This, in turn, changes the expression of many genes that trigger inflammatory and antiviral responses. In severe COVID-19, SARS-CoV-2 triggers a chronic immune reaction that is instructed by TGF-β [29]. Excessively elevated TGF-β activity is also a key feature of COVID-19 cytokine storm [30]. During SARS-CoV-2 infection and replication, mTOR, a serine-threonine kinase involved in cell proliferation and cellular metabolism, was found to be active [31]. mTOR is involved in the interaction of adapter proteins MyD88, TLR9, and IRF-7 in plasmacytoid dendritic cells (pDCs), which leads to the transcriptional activation of type-I interferon (IFN) genes. The interleukin 18 binding protein (IL18BP) gene encodes a soluble inhibitor and carrier that keeps proinflammatory cytokine IL-18, a natural killer (NK) cell amplifier in check [32, 33]. Both T-cells and NK cells both produce IFN-γ, and IL-18 plays a critical role in this process. IL-18, along with other cytokines (IFN-γ, IL-1, IL-6, TNF), are elevated in cytokine storm and are thought to have central immunopathologic roles in COVID-19 [34].

Altered TCR diversity and aberrant cytokine expression in perturbed subset

We compared the TCR repertoires of 270 CCDs and 40 healthy donors using Nanostring's TCR diversity panel. The average TCR diversity score in CCD samples did not depart from the average healthy donor sample at any time point (Fig. 3A, B). However, the T-cell receptor (TCR) diversity score in perturbed subset P1 was significantly elevated compared to healthy donors (p = 1.18X10−7) (Fig. 3C), with unique T cell clonal expansion. Further analysis of the VJ gene combination revealed a significantly increased expression of 7 VJ pairs (TRAV9.1_TCRVA_014.1, TRBV6.8_TCRVB_016.1, TRAV7_TCRVA_008.1, TRGV9_ENST00000444775.1, TRAV18_TCRVA_026.1, TRGV4_ENST00000390345.1, TRAV11_TCRVA_017.1) while 54 pairs declined with FDR < 0.05 (Additional file 4: Table S4). TCR is crucial in T cell-mediated viral clearance and TCR bias is notable in various diseases [35]. Clonotypic T cell receptors (TCRs), which identify a peptide (8–15 amino acids) presented by major histocompatibility complex (MHC), direct the signaling that T cells use to orchestrate adaptive immunity [36, 37]. During the acute stages of infection, peptide-MHC complex (pMHC) recognition by TCR causes naive T cells to become activated and differentiate into diverse functional subsets, which eradicates invasive pathogens [38]. The variable (V), junctional (J), and constant (C) regions make up each of the two TCR chains (α and β) [39]. The diversity (D) region establishes an essential chain by joining the V and J areas. Thus, a functional and highly varied TCR repertoire is created by the TCR recombination process, which also develops highly diverse complementarity-determining regions (CDRs) localized in the TCR α and β chains. Luo et al. studied the blood T cells from recovered COVID-19 patients PBMCs from 1 to 6 weeks, and their TCR repertoires and immune metabolic processes were analyzed using single-cell TCR-seq and RNA-seq [36]. They observed that the TCR repertoire's diversity increased in patients who were discharged but it quickly went back to its baseline levels after 1 week after the SARS-CoV2 virus was eliminated. A significant shift in gene signatures from antiviral response to metabolic adaptation correlated with the dynamics of T cell repertoire in the study. By using ImmunoSEQ technology, Wang et al. studied the TCR repertoires of COVID-19 patients' PBMCs obtained before (baseline), during (acute), and after rehabilitation (convalescent) and they discovered that these patients TCR repertoires differed noticeably from healthy controls in terms of decreased TCR diversity, abnormal complementary-determining region 3 (CDR3) length, different TRBV/J gene usage, and higher TCR sequence overlap [40].

Fig. 3
figure 3

Changes in TCR diversity. A. TCR diversity score of all samples over time. B. Mean changes in TCR diversity score from HD to CCR. Points show estimates, lines show 95% confidence intervals. C. TCR diversity scores in HD, CCD, and perturbed CCD clusters (P1, P2). P-values contrast P1 and P2 to HD

Multiplexed cytokine analysis was performed on 18 healthy donors, 6 P1 CCD, and 10 P2 CCD. Of the 48 cytokines analyzed, the P2 cluster had none that differed significantly from healthy donors, and the P1 cluster had 3 cytokines with significant differences from healthy donor: stem cell factor (SCF), Monocyte Chemoattractant Protein-1 (MCP-1), and Stem Cell Growth Factor-beta (SCGF-b) (Fig. 4). SCF overexpression is notable in inflammatory conditions. Binding of SCF to c-Kit leads to activation of multiple pathways, including phosphatidyl-inositol-3 (PI3)-kinase, phospholipase C (PLC)-gamma, Src kinase, Janus kinase (JAK)/Signal Transducers and Activators of Transcription (STAT) and mitogen-activated protein (MAP) kinase pathways. SCF is an important growth factor for mast cells, promoting their generation from CD34 + progenitor cells. In vitro, SCF induces mast cells survival, adhesion to extracellular matrix, and degranulation, leading to the expression and release of histamine, proinflammatory cytokines, and chemokines. SCF also induces eosinophil adhesion and activation. SCF is upregulated in inflammatory conditions both in vitro and in vivo in humans and mice [41]. MCP-1 elevation is suggestive of increased viral clearance from the CNS [42, 43]. SCGF, which was also marginally elevated in the healthy donor compared to the 2 CCD groups, may be a marker for hematopoietic recovery [44].

Fig. 4
figure 4

Multiplexed cytokine analysis from a limited time window comparing healthy donor (HD) vs. the highly perturbed CCD clusters (P1 and P2) identified by gene expression profiling. The 3 cytokines with statistically significant departures from HD in either P1 or P2 are shown

Demographic and laboratory data did not identify significant differences between the 2 perturbed clusters compared to healthy donor or “other” CCD samples (Table 4). We were unable to perform a look-back review of donors concerning the occurrence/persistence of signs or symptoms consistent with long-COVID syndrome in our cohort.

Table 4 COVID-19 Convalescent Plasma Donor Demographics Comparing P1, P2 Perturbed Sample Clusters (P1, P2) with Other CCD and Healthy Donors


We evaluated the transcriptome of peripheral blood leukocytes from people who had recovered from COVID-19 and donated convalescent plasma. At the time of the donation, the CCD had no COVID-19 symptoms, tested negative for SARS-CoV2, and were considered healthy because they passed a blood donor health history questionnaire. The CCD differed from healthy donors in several respects. When compared to healthy donors, CCD had significantly higher leukocyte, lymphocyte, and monocyte counts (early on in convalescence), as noted previously with other viral infections as well [45, 46]. More importantly, CCD demonstrated significant differences in peripheral blood leukocyte transcriptomes. In a subset of CCD with highly perturbed transcriptomics, cytokine levels were also abnormal in PBMC samples collected months after convalescence. These results suggest that the immune dysregulation occurring during acute infection in COVID-19 persists for several months post-infection.

Our study is unique in that we analyzed convalescent donors over a long period. Some studies have evaluated people serially with SARS-CoV-2 and found persistent changes in cellular immunity, but only studied patients for 6 to 10 weeks following resolution of COVID-19 [47, 48]. Our longitudinal assessment of PBMC samples from CCD identified unique transcriptomic trends. The CCD samples were collected at various time intervals following the diagnosis of COVID-19. The samples were collected from a few weeks to more than 6 months post-symptom resolution. While we found some differences in gene expression among CCD at all time intervals, the nature of transcriptomes varied with time. Interestingly, when compared to healthy subjects, the number of differentially expressed genes increased over time, peaked at about 120 to 150 days post-symptom resolution, and then fell during the remainder of the study period.

The function of the differentially expressed genes also changed with time. Initially, less than 90 days post-symptom resolution, genes in interferon signaling, TNF signaling, and cell exhaustion pathways were expressed at high levels in CCD. Later, as the expression of CTLA-4, an inhibitor of T-cell function and marker cell exhaustion, fell in CCD leukocytes, the expression of genes in TGF-β signalizing, TNF signaling, IL-6 signaling, and myeloid activation increased in CCD leukocytes. After 120 to 149 days post-symptom resolution, the number of differentially expressed genes fell, but the proinflammatory genes OSM, PTGS2, and IL1B remained up-regulated. The expression of immunological checkpoint inhibitor CTLA4 is enhanced on the surface of T-cells due to induction of INF-γ production by neutrophils and monocytes, which are abundant in the peripheral blood of people with COVID-19 [49]. An earlier analysis of publicly available transcriptomic databases found that the number and intensities of these inhibitory receptors were higher in SARS-CoV-2 infections compared to SARS-CoV-1, influenza, and respiratory syncytial virus infections [50]. Besides CTLA4, an increase in activated CXCR4 + T cells homing to the lungs is associated with fatal COVID-19 [51]. Hou et al. identified a significant enhancement of the expression of inhibitory receptors, which included CTLA-4 on SARS-CoV-2–specific CD4 + T cells (suggesting an exhausted phenotype) even though the quantity of SARS-CoV-2–specific CD4 + T cells in convalescent COVID-19 patients was maintained after a year of recovery [52]. In convalescent subjects with mild/moderate symptoms, 27–47 days after symptom onset, the T-cell differentiation regulation and memory T cell-related gene CXCR4 were upregulated along with FOS, JUN, CD69, and CD83 [53]. Hence, both altered CTLA4 and CXCR4 expression levels may play a critical role in the severity and fatality of the SARS-CoV-2 infection, as well as during convalescence.

OSM, CXCL2, and CCL3/CCL3L1/CCL3L3 (jointly measured with a single probe) initially have wide expression ranges spanning from the normal range of healthy donor samples to greater than 16-fold increases from the healthy donor mean. By 200 days, these extreme over-expression values are no longer observed, and these genes’ mean expression returns to the healthy donor mean. The OSM gene encodes the protein Oncostatin M, a pleiotropic cytokine that stimulates IL-6. Circulating OSM positively correlates with COVID-19 severity. IL-6, a proinflammatory cytokine, drives immune dysregulation and respiratory failure leading to higher mortality [54, 55]. The chemokine CXCL2 is critical for macrophage, monocyte, and neutrophil migration and is also known to facilitate the clearance of SARS-CoV2 in the absence of CD4 + and CD8 + T cells or neutralizing antibodies beyond 12 days of infection [56]. The CCL3L3 gene encodes the CCL3 protein (MIP-1), one of the chemokine families with diverse functions based on the C–C motif. CCL3 is a neutrophil chemotaxis protein that acts as a ligand for CCR1, CCR3, and CCR5. Neutrophils play a significant role in COVID-19 severity, as CCL3 is upregulated in severe COVID-19 [57] [58]. IL1B shows a similar pattern, but it did not return to the healthy donor average by 200 days. Interleukin (IL)-1β, a potent proinflammatory cytokine, plays a significant role in the host defense response to infection and injury. Studies have shown elevated levels of IL1β during COVID-19 infection [59]. Additionally, the IL1 family of cytokines plays a key role in inducing cytokine storm in poorly controlled COVID-19 infection. Furthermore, in a recent clinical study of 88 hospitalized subjects with SARS-CoV-2 infection, blockage of IL1β with canakinumab demonstrated better clinical outcomes [59]. IFNA6 and HERC5 both show consistent down-regulation from healthy donors, but with high outliers > fourfold above the healthy donor mean. These genes remain suppressed below the healthy donor average beyond 200 days. Type I interferon subtype IFNA6 has been reported in patients infected with COVID-19 in the context of platelet degranulation and B cell maturation [60,61,62]. E3 ligase HECT and RCC1-containing protein 5 (HERC5) regulate interferon-stimulated gene 15 (ISG15) signaling in response to SARS-CoV-2 and other viral infections [63].

A subset of “highly perturbed” CCD had more marked changes in gene expression. These gene expression changes in the perturbed CCD seemed transient. Of the 21 patients with a “highly perturbed” sample, 11 had multiple timepoints collected. Among these 11 individuals, only 1 was highly perturbed at multiple timepoints, transitioning from cluster P2 at 88 days to cluster P1 at 117 days. A subgroup of these perturbed donors had gene expression changes showing interferon production and innate immune system activation, lower levels of anti-COVID antibodies and increased TCR diversity.

It is unclear why immune changes were found in CCD up to 6-months post-symptom resolution. However, it has proven difficult to find the immunological "bridge" that connects acute COVID-19 and post-COVID-19 syndrome [64, 65]. Careful annotation of the clinical symptomatology is a crucial step in understanding the pathophysiology of the post-COVID syndrome. It may be possible to separate disease drivers by separating residual symptoms of the acute disease site from new symptoms that may develop after the acute disease recovery. Moreover, confounding factors may also include post-traumatic stress disorder (PTSD)-related elements, which can make it difficult for patients to accurately assess their own clinical symptoms and necessitate comprehensive neuropsychiatric assessments [65]. Additionally, persistence of SARS-COV-2 has been detected by RT-PCR in respiratory specimens for approximately 2 to 3 weeks post-infection, in some cases 4 to 8 weeks [66]. SARS-CoV-2 can be detected in feces for a longer period than in respiratory specimens [66, 67]. One study found that SARS-CoV-2 could be detected in respiratory samples for a median of 14 days and in feces for a median of 19 days [68]. Another study found that it could be detected in feces for 10 weeks [67]. The persistent shedding of SARS-CoV2 is not thought to be due to reinfection but is more likely the result of release of sequestered virus or mutation of the original virus. It is also possible latent virus is reactivated. However, persistent SARs-CoV2 has not been detected 6-months post-symptom resolution.

The presence of prolonged changes in immune cell transcriptomes post-COVID-19 is consistent with other studies reporting prolonged symptoms in people who have recovered from acute infections. Many people experience post-acute sequelae of COVID-19 (PASC) which is also known as long COVID or long haulers syndrome. These people experience fatigue, tiredness, dyspnea, shortness of breath, chest pain, joint pain, and perceived cognitive impairment. One study found that 93% of people hospitalized for COVID-19 experienced PASC [69]. In the same study, among people who had visited a clinic, 55% had at least one of these persistent symptoms 25 to 89 days post-diagnosis, and 67% had at least one persistent symptom 90 to 174 days post-diagnosis. After 175 days, 64% of people experienced symptoms [69]. It is possible that our study included CCD with these symptoms. All the CCD were required to pass a blood donor health history screen and to have had a normal body temperature to donate. However, the blood donor history screen is somewhat generic, and it is possible that some donors had the somewhat non-specific symptoms of PASC, which were not captured during the health screen.

Post-acute sequelae of COVID-19 have some similarities to chronic fatigue syndrome, which is characterized by fatigue, depression, memory loss, and discomfort. Inflammatory reactions and elevated cytokine levels likely contribute to some of these symptoms. Cytokines found elevated in some chronic fatigue syndrome patients include interferon-γ, IL-6, IL-1, IL-2, and TGF-β [70]. Our study found that people who had recovered from COVID-19 were afebrile, relatively healthy but still had elevated cytokine and chemokine gene expression levels and well as increased cytokine expression throughout the 6-month study period, which suggests that immune dysregulation and immune system activation may be responsible for PASC. Consistent with our findings was another recently published report of persistent immunological dysfunction characterized by elevated proinflammatory cytokine (IFN-β, IFN-λ1, IFN-γ, CXCL9, CXCL10, IL-8, and sTIM-3) levels up to 8 months after mild-moderate COVID-19 infection. Furthermore, these were elevated in individuals with or without clinically identifiable long COVID syndrome when compared to individuals who were infected with other (non-COVID) prevalent coronaviruses or in unexposed healthy control groups [71].


Overall, our study identified important gene expression trends in CCD compared to healthy donors in the post-acute period. These pathways and changes in expression levels may help inform the pathophysiology of the post-acute syndrome, not only for COVID but also for other viral diseases. Our data may serve as the basis for risk modification strategies in the period of active infection. Avenues forward will also inform potential druggable targets during convalescence from COVID-19.

Data availability

The raw data and normalized counts are available online on Gene Expression Omnibus (GEO) in the database repository for the Nanostring host immune responses (GSE211378) and TCR diversity (GSE211394).



COVID-19 convalescent donor


Healthy donors


Severe acute respiratory syndrome coronavirus-2


Body Mass Index


Absolute neutrophil counts


Absolute monocyte counts


Absolute lymphocyte counts


Plasmacytoid dendritic cells






Natural killer cells


T cell receptor


Major histocompatibility complex


Complementarity-determining regions




Phospholipase C


Janus kinase


Signal Transducers and Activators of Transcription


Mitogen-activated protein


Stem Cell Growth Factor-beta


Mitogen-activated protein


HECT and RCC1-containing protein 5


Interferon-stimulated gene


Differentially expressed genes


  1. Zhai Y, Franco LM, Atmar RL, Quarles JM, Arden N, Bucasas KL, Wells JM, Nino D, Wang X, Zapata GE, et al. Host transcriptional response to influenza and other acute respiratory viral infections–A prospective cohort study. PLoS Pathog. 2015;11: e1004869.

    Article  Google Scholar 

  2. Pommerenke C, Wilk E, Srivastava B, Schulze A, Novoselova N, Geffers R, Schughart K. Global transcriptome analysis in influenza-infected mouse lungs reveals the kinetics of innate and adaptive host immune responses. PLoS ONE. 2012;7: e41169.

    Article  CAS  Google Scholar 

  3. Huang Y, Zaas AK, Rao A, Dobigeon N, Woolf PJ, Veldman T, Oien NC, McClain MT, Varkey JB, Nicholson B, et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet. 2011;7: e1002234.

    Article  CAS  Google Scholar 

  4. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020.

    Article  Google Scholar 

  5. Maurya R, Shamim U, Chattopadhyay P, Mehta P, Mishra P, Devi P, Swaminathan A, Saifi S, Khare K, Yadav A. Human-host transcriptomic analysis reveals unique early innate immune responses in different sub-phenotypes of COVID-19. Clin Transl Med. 2022;12: e856.

    Article  CAS  Google Scholar 

  6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan China. Intensive Care Med. 2020;46:846–8.

    Article  CAS  Google Scholar 

  7. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K, Panis M, Sachs D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(1036–1045): e1039.

    Google Scholar 

  8. Park A, Iwasaki A. Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27:870–8.

    Article  CAS  Google Scholar 

  9. Tartaro DL, Neroni A, Paolini A, Borella R, Mattioli M, Fidanza L, Quong A, Petes C, Awong G, Douglas S. Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia. Commun Biol. 2022.

    Article  Google Scholar 

  10. Cruz-Pulido D, Ouma WZ, Kenney SP. Differing coronavirus genres alter shared host signaling pathways upon viral infection. Sci Rep. 2022;12:1–12.

    Article  Google Scholar 

  11. Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, Fang Y, Hall Y, Zekeng EG, Lüdtke A, et al. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol. 2017;18:4.

    Article  Google Scholar 

  12. Petzke MM, Volyanskyy K, Mao Y, Arevalo B, Zohn R, Quituisaca J, Wormser GP, Dimitrova N, Schwartz I, Norris SJ. Global transcriptome analysis identifies a diagnostic signature for early disseminated Lyme disease and its resolution. mBio. 2020;11:e00047-00020.

    Article  Google Scholar 

  13. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, Chu HY. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4:e210830–e210830.

    Article  Google Scholar 

  14. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063.

    Article  CAS  Google Scholar 

  15. Hoagland DA, Møller R, Uhl SA, Oishi K, Frere J, Golynker I, Horiuchi S, Panis M, Blanco-Melo D, Sachs D. Leveraging the antiviral type-I interferon system as a first line defense against SARS-CoV-2 pathogenicity. Immunity. 2021.

    Article  Google Scholar 

  16. Woolsey C, Borisevich V, Prasad AN, Agans KN, Deer DJ, Dobias NS, Heymann JC, Foster SL, Levine CB, Medina L. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol. 2021;22:86–98.

    Article  CAS  Google Scholar 

  17. Batchu S, Yu S. Age-associated ligand-receptor interactions imputed from nasopharyngeal transcriptomes of COVID-19 patients. Immunol Invest. 2021.

    Article  Google Scholar 

  18. Abikhair Burgo M, Roudiani N, Chen J, Santana AL, Doudican N, Proby C, Felsen D, Carucci JA. Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. JCI Insight. 2018.

    Article  Google Scholar 

  19. Dai Y, Wang J, Jeong H-H, Chen W, Jia P, Zhao Z. Association of CXCR6 with COVID-19 severity: delineating the host genetic factors in transcriptomic regulation. BioRxiv. 2021.

    Article  Google Scholar 

  20. Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, Surapaneni NS, Matusov YP, Chiang GC, Kassar AG. Cell-type-specific immune dysregulation in severely Ill COVID-19 patients. Cell Rep. 2021;34: 108590.

    Article  CAS  Google Scholar 

  21. Sabioni L, De Lorenzo A, Lamas C, Muccillo F, Castro-Faria-Neto HC, Estato V, Tibirica E. Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: evaluation by laser Doppler perfusion monitoring and cytokine/chemokine analysis. Microvasc Res. 2021;134: 104119.

    Article  CAS  Google Scholar 

  22. Zou M, Su X, Wang L, Yi X, Qiu Y, Yin X, Zhou X, Niu X, Wang L, Su M. The molecular mechanism of multiple organ dysfunction and targeted intervention of COVID-19 based on time-order transcriptomic analysis. Front Immunol. 2021.

    Article  Google Scholar 

  23. Sohn KM, Lee S-G, Kim HJ, Cheon S, Jeong H, Lee J, Kim IS, Silwal P, Kim YJ, Paik S. COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. J Korean Med Sci. 2020.

    Article  Google Scholar 

  24. Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O. NF-κB pathway as a potential target for treatment of critical stage COVID-19 patients. Front Immunol. 2020;11:3446.

    Article  Google Scholar 

  25. Nilsson-Payant BE, Uhl S, Grimont A, Doane AS, Cohen P, Patel RS, Higgins CA, Acklin JA, Bram Y, Chandar V. The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication. J Virol. 2021;95:e01257-e11221.

    Article  CAS  Google Scholar 

  26. Hasankhani A, Bahrami A, Sheybani N, Aria B, Hemati B, Fatehi F, Javanmard G, Rezaee M, Kastelic J, Barkema H. Differential co-expression network analysis reveals key hub-high traffic genes as potential therapeutic targets for COVID-19 pandemic. Front Immunol. 2021;12:789317–789317.

    Article  CAS  Google Scholar 

  27. Vastrad B, Vastrad C, Tengli A. Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods. 3 Biotech. 2020;10:1–65.

    Article  Google Scholar 

  28. Farahani M, Niknam Z, Amirabad LM, Amiri-Dashatan N, Koushki M, Nemati M, Pouya FD, Rezaei-Tavirani M, Rasmi Y, Tayebi L. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother. 2022;145: 112420.

    Article  CAS  Google Scholar 

  29. Ferreira-Gomes M, Kruglov A, Durek P, Heinrich F, Tizian C, Heinz GA, Pascual-Reguant A, Du W, Mothes R, Fan C. SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nat Commun. 2021;12:1–14.

    Article  Google Scholar 

  30. Shen W-X, Luo R-C, Wang J-Q, Chen Z-S. Features of cytokine storm identified by distinguishing clinical manifestations in COVID-19. Front Public Health. 2021;9:614.

    Article  Google Scholar 

  31. Ramaiah MJ. mTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19. Gene reports. 2020;20: 100765.

    Article  CAS  Google Scholar 

  32. Dinarello C, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289.

    Article  Google Scholar 

  33. Harms RZ, Creer AJ, Lorenzo-Arteaga KM, Ostlund KR, Sarvetnick NE. Interleukin (IL)-18 binding protein deficiency disrupts natural killer cell maturation and diminishes circulating IL-18. Front Immunol. 2017;8:1020.

    Article  Google Scholar 

  34. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–73.

    Article  CAS  Google Scholar 

  35. Wang P, Jin X, Zhou W, Luo M, Xu Z, Xu C, Li Y, Ma K, Cao H, Huang Y. Comprehensive analysis of TCR repertoire in COVID-19 using single cell sequencing. Genomics. 2021;113:456–62.

    Article  CAS  Google Scholar 

  36. Luo L, Liang W, Pang J, Xu G, Chen Y, Guo X, Wang X, Zhao Y, Lai Y, Liu Y. Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. Cell discovery. 2021;7:1–17.

    Article  Google Scholar 

  37. Tang-Huau T-L, Gueguen P, Goudot C, Durand M, Bohec M, Baulande S, Pasquier B, Amigorena S, Segura E. Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway. Nat Commun. 2018;9:1–12.

    Article  CAS  Google Scholar 

  38. Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol. 2012;12:295–305.

    Article  CAS  Google Scholar 

  39. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V (D) J recombination. Cell. 2002;109:S45–55.

    Article  CAS  Google Scholar 

  40. Wang G, Wang Y, Jiang S, Fan W, Mo C, Gong W, Chen H, He D, Huang J, Ou M. Comprehensive analysis of TCR repertoire of COVID-19 patients in different infected stage. Genes Genom. 2022.

    Article  Google Scholar 

  41. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol. 2006;533:327–40.

    Article  CAS  Google Scholar 

  42. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res: the official journal of the International Society for Interferon and Cytokine Research. 2009;29:313–26.

    Article  CAS  Google Scholar 

  43. Carmen J, Gowing G, Julien JP, Kerr D. Altered immune response to CNS viral infection in mice with a conditional knock-down of macrophage-lineage cells. Glia. 2006;54:71–80.

    Article  Google Scholar 

  44. Ito C, Sato H, Ando K, Watanabe S, Yoshiba F, Kishi K, Furuya A, Shitara K, Sugimoto S, Kohno H, et al. Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation. Bone Marrow Transplant. 2003;32:391–8.

    Article  CAS  Google Scholar 

  45. Kennedy AE, Cook L, Breznik JA, Cowbrough B, Wallace JG, Huynh A, Smith JW, Son K, Stacey H, Ang J, et al. Lasting changes to circulating leukocytes in people with mild SARS-CoV-2 infections. Viruses. 2021;13:2239.

    Article  CAS  Google Scholar 

  46. Han Q, Wen X, Wang L, Han X, Shen Y, Cao J, Peng Q, Xu J, Zhao L, He J, Yuan H. Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms. J Clin Lab Anal. 2020;34: e23191.

    Article  CAS  Google Scholar 

  47. Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, Palomba P, Mirabella M, Cascioli S, Palange P, et al. Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol. 2020;11: 610300.

    Article  CAS  Google Scholar 

  48. Liu J, Yang X, Wang H, Li Z, Deng H, Liu J, Xiong S, He J, Feng X, Guo C, et al. Analysis of the long-term impact on cellular immunity in COVID-19-recovered individuals reveals a profound NKT cell impairment. mBio. 2021.

    Article  Google Scholar 

  49. Aghbash PS, Eslami N, Shamekh A, Entezari-Maleki T, Baghi HB. SARS-CoV-2 infection: the role of PD-1/PD-L1 and CTLA-4 axis. Life Sci. 2021;270: 119124.

    Article  CAS  Google Scholar 

  50. Sharif-Askari NS, Sharif-Askari FS, Mdkhana B, Al Heialy S, Alsafar HS, Hamoudi R, Hamid Q, Halwani R. Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection. Mol Ther-Methods Clin Dev. 2021;20:109–21.

    Article  Google Scholar 

  51. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, Murray V, Gill G, Greene WC, Vasquez J. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep. 2021;36: 109414.

    Article  CAS  Google Scholar 

  52. Hou H, Zhang Y, Tang G, Luo Y, Liu W, Cheng C, Jiang Y, Xiong Z, Wu S, Sun Z. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. J Allergy Clin Immunol. 2021;148(1481–1492): e1482.

    Google Scholar 

  53. Li X, Garg M, Jia T, Liao Q, Yuan L, Li M, Wu Z, Wu W, Bi Y, George N. Single-cell analysis reveals the immune characteristics of myeloid cells and memory T cells in recovered COVID-19 patients with different severities. Front Immunol. 2022.

    Article  Google Scholar 

  54. Shekhawat J, Gauba K, Gupta S, Purohit P, Mitra P, Garg M, Misra S, Sharma P, Banerjee M. Interleukin-6 perpetrator of the COVID-19 cytokine storm. Indian J Clin Biochem. 2021;36:440–50.

    Article  CAS  Google Scholar 

  55. Chen LY, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respiratory Soc. 2020.

    Article  Google Scholar 

  56. Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021;19:976–88.

    Article  CAS  Google Scholar 

  57. Didangelos A. COVID-19 hyperinflammation: what about neutrophils? MSphere. 2020;5:e00367-e1320.

    Article  CAS  Google Scholar 

  58. Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, Sivapatham S, Jacobs A, Bachli E, Rudiger A. A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Rep Med. 2021;2: 100166.

    Article  CAS  Google Scholar 

  59. Mardi A, Meidaninikjeh S, Nikfarjam S, Majidi Zolbanin N, Jafari R. Interleukin-1 in COVID-19 infection: immunopathogenesis and possible therapeutic perspective. Viral Immunol. 2021;34:679–88.

    Article  CAS  Google Scholar 

  60. Galbraith MD, Kinning KT, Sullivan KD, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter R, Jordan KR, Russell S. Specialized interferon action in COVID-19. Proc Natl Acad Sci. 2022;119: e2116730119.

    Article  CAS  Google Scholar 

  61. Wang JY, Zhang W, Roehrl MW, Roehrl VB, Roehrl MH. An autoantigen profile of human A549 lung cells reveals viral and host etiologic molecular attributes of autoimmunity in COVID-19. J Autoimmun. 2021;120: 102644.

    Article  CAS  Google Scholar 

  62. Daamen AR, Bachali P, Owen KA, Kingsmore KM, Hubbard EL, Labonte AC, Robl R, Shrotri S, Grammer AC, Lipsky PE. Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. Sci Rep. 2021;11:1–19.

    Article  Google Scholar 

  63. Mathieu NA, Paparisto E, Barr SD, Spratt DE. HERC5 and the ISGylation pathway: critical modulators of the antiviral immune response. Viruses. 2021;13:1102.

    Article  CAS  Google Scholar 

  64. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD. Immunology of COVID-19: current state of the science. Immunity. 2020;52:910–41.

    Article  CAS  Google Scholar 

  65. Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194–202.

    Article  CAS  Google Scholar 

  66. Zapor M. Persistent detection and infectious potential of SARS-CoV-2 virus in clinical specimens from COVID-19 patients. Viruses. 2020.

    Article  Google Scholar 

  67. van Doorn AS, Meijer B, Frampton CMA, Barclay ML, de Boer NKH. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Ther. 2020;52:1276–88.

    Google Scholar 

  68. Morone G, Palomba A, Iosa M, Caporaso T, De Angelis D, Venturiero V, Savo A, Coiro P, Carbone D, Gimigliano F, et al. Incidence and persistence of viral shedding in COVID-19 post-acute patients with negativized pharyngeal swab: a systematic review. Front Med (Lausanne). 2020;7:562.

    Article  Google Scholar 

  69. LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, Tipton M, Haberman J, Massey BR, McFann K, et al. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect Dis. 2021;21:677.

    Article  CAS  Google Scholar 

  70. Yang T, Yang Y, Wang D, Li C, Qu Y, Guo J, Shi T, Bo W, Sun Z, Asakawa T. The clinical value of cytokines in chronic fatigue syndrome. J Transl Med. 2019;17:213.

    Article  Google Scholar 

  71. Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier C, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022.

    Article  Google Scholar 

Download references


The authors would like to thank the NIH Dowling apheresis and DTM/CCE staff for specimen collection and donor care.


Open Access funding provided by the National Institutes of Health (NIH). This research was supported by the intramural research program of the NIH, NIH Clinical Center.

Author information

Authors and Affiliations



M.G.; Performed experiments, analyzed data, and co-wrote the paper. P.D.; Performed gene expression data analysis and co-wrote the paper. M.G. and P.D.; Contributed equally overall. L.S.; Performed cytokine experiments and analyzed data. L.C., K.W., V.D.; Collected and provided patient samples as part of their original covid convalescent donor study. M.O., A.D., M.T.S., O.L.R., C.B., W.B., I.D., and R.S.; Analyzed the data and co-wrote the manuscript. S.R.P., J.P., and D.F.S.; Conceptualized the study, supervised the research, and co-wrote the paper. S.R.P. and D.F.S.; Contributed equally as senior authors. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Sandhya R. Panch or David F. Stroncek.

Ethics declarations

Ethics approval and consent to participate

162 CCD and 40 healthy donor controls were enrolled prospectively in an IRB-approved protocol (Clinical Trials Number: NCT04360278) and provided written informed consent to participate in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1

. Genes detected by the nCounter@ Human Host Response panel.

Additional file 2: Table S2

. Genes detected by the nCounter@ Human TCR diversity panel.

Additional file 3: Table S3

. Expression of each gene by CCDs at 26-89 days, 90-119 days, 120-149 days and 150-241 days.

Additional file 4: Table S4

. Comparison of the expression of VJ gene combinations among CCDs and healthy donors.

Additional file 5:

Fig. S1. A)Total Anti-SARS-CoV-2, B)IgG Anti-SARS-CoV2, and C)Neutralizing antibody titers in individuals who donated on one or more occasions.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gedda, M.R., Danaher, P., Shao, L. et al. Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors. J Transl Med 20, 587 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: